Endoplasmic reticulum oxidoreductin-1 alpha (ERO1A)

Endoplasmic reticulum oxidoreductin-1 alpha (ERO1A) is a flavin adenine dinucleotide (FAD)-dependent oxidoreductase essential for oxidative protein folding within the endoplasmic reticulum (ER). It functions by transferring electrons from protein disulfide isomerase (PDI) to molecular oxygen, thereby generating disulfide bonds in nascent polypeptides (UniProt Q96HE7). In the context of disease, ERO1A is significantly overexpressed in numerous solid tumors, where it is regulated by hypoxia-inducible factor 1-alpha (HIF-1α) and promotes tumor growth, angiogenesis, and resistance to therapy (PubMed: 28844478). Beyond oncology, ERO1A plays a role in the pathogenesis of type 2 diabetes by contributing to ER stress-induced beta-cell failure (PubMed: 21903747). Pharmacological inhibition of ERO1A, using experimental compounds such as EN460, aims to induce proteotoxic stress and apoptosis specifically in cancer cells that are highly dependent on its activity (PubMed: 23143213). However, the development of ERO1A-targeted therapies must carefully manage potential toxicities in normal secretory organs like the pancreas and liver.

Other names

ERO1-LERO1-alphaERO1LERO1-like protein alphaOxidoreductin-1-L-alphaERO1-like alpha

Inhibition of the oxidase activity of ERO1A to disrupt the formation of disulfide bonds in the endoplasmic reticulum, leading to the accumulation of unfolded proteins, induction of the unfolded protein response (UPR), and subsequent apoptosis in susceptible cells, particularly under hypoxic conditions.